Ono Pharmaceutical Co., Ltd.

Masakuni Kurono

Shingo Yamamoto

Masaya Kokubo

Hiroshi Hagiya

Shingo Hotta

Ryosuke Hanada

Kenichi Kouda

Hiroshi Tokura

Yoshinori Nomura

Atsushi Yoshida

A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

STING agonistic compound

A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):

Sting agonistic compound

The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example. 

BRK inhibitory compound

The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these. 

Growing community of inventors

Osaka, Japan

Masakuni Kurono